Flexifyme

Manjeet Singh and Amit Bhayani are Season 3's most personally pain-to-platform founders. Manjeet's founding story is deeply personal: diagnosed with Lumbar Spondylosis, he faced limited success from traditional treatments and the daunting prospect of spinal surgery. Rather than accepting surgery, he embarked on a research journey guided by orthopedic doctors, physiotherapists, and yoga therapists, eventually discovering that a combination of specific physiotherapy exercises, targeted yoga therapy, and consistent practice could naturally reverse his condition without surgical intervention. That personal recovery experience became FlexifyMe's entire founding thesis: if Manjeet could avoid surgery through the right combination of physiotherapy and yoga, millions of chronic pain sufferers worldwide could too, if they had access to the same expert guidance and personalised treatment protocols.

FlexifyMe is India's most technologically advanced chronic pain management platform, combining AI-driven posture analysis and motion monitoring with live one-on-one sessions with certified physiotherapists and yoga therapists to provide personalised, data-driven, trackable chronic pain treatment that moves away from subjective, symptom-based care. The patient journey follows four structured steps: AI Self-Assessment (3-minute camera-based posture analysis identifying alignment issues and joint mobility limitations), Customised Plan (personalised treatment protocol integrating yoga, physiotherapy, and AI-guided self-practice exercises), Live Sessions (25 one-on-one sessions with certified physiotherapists over 6 months), and Progress Tracking (AI monitors improvement in posture, mobility, and pain levels over time).

Amount Asked: ₹1 crore Equity Offered: 2% Implied Pre-Money Valuation: ₹50 crore

Manjeet and Amit walked into Season 3 Episode 38 (the Season Finale) as the episode's most personally compelling health-tech founders. Manjeet opened with his own Lumbar Spondylosis story, the failed treatments, the surgery prospect, and the natural recovery that became FlexifyMe's founding mission. The personal narrative immediately established credibility: a founder who has experienced chronic pain and recovered naturally has authenticity that no medical degree can substitute. The AI posture analysis was demonstrated live: a Shark stood before the camera, and within 3 minutes the system generated a comprehensive postural analysis showing alignment issues, joint mobility limitations, and suggested interventions. The technology demonstration was Season 3 Episode 38's most practically impressive health-tech showcase. The commercial metrics validated the mission: 50,000 plus customers in Year 1, 2,000 plus subscribers from 26 plus countries, and a subscription model (₹6,000 to ₹16,000 for 6 months) that generated sustainable recurring revenue.

Aman Gupta exited because he did not understand the chronic pain management market deeply enough to add strategic value beyond capital. Anupam Mittal exited on market understanding grounds, questioning whether the subscription pricing and customer acquisition model would scale efficiently in India's price-sensitive healthcare market. Vineeta Singh did not invest, finding the health-tech and physiotherapy domain outside her consumer beauty brand expertise. Amit Jain showed interest during the pitch and reportedly contributed to the deal structure alongside Namita (some sources indicate his participation in the final investment alongside Namita, while others credit only Namita). Namita Thapar was the most domain-aligned Shark: as Emcure Pharmaceuticals' Executive Director, she understood chronic pain management, physiotherapy market dynamics, and healthcare platform scaling at the deepest possible institutional level.

The founders asked ₹1 crore for 2% equity (₹50 crore valuation). After negotiations, the deal settled at ₹50 lakhs for 1.32% equity plus ₹50 lakhs debt at 10% interest for 2 years (₹37.88 crore valuation on the equity component, total investment ₹1 crore). The equity-debt split maintained the founders' ₹1 crore capital requirement while providing Namita downside protection through the debt component. The 1.32% equity preserved maximum founder ownership while giving Namita meaningful upside participation.

Manjeet Singh and Amit Bhayani accepted Namita Thapar's offer of ₹50 lakhs for 1.32% equity plus ₹50 lakhs debt at 10% interest for 2 years, valuing FlexifyMe at ₹37.88 crore. Namita's Emcure pharmaceutical ecosystem, chronic pain management domain expertise, healthcare distribution network, and personal conviction in the chronic pain market made her the most strategically irreplaceable Shark for FlexifyMe. The deal was Season 3's final investment, closing out the entire season with a health-tech deal from the healthcare Shark.

"Our mission is simple: by combining technology, licensed physiotherapists and rigorous progress tracking, we are making the journey to a pain-free life scientific, objective and measurable," said co-founder Manjeet Singh. FlexifyMe's post-Shark Tank trajectory is Season 3's most dramatically funded health-tech success story. The company raised a $1 million seed round led by Flipkart Ventures (with participation from investors including Ravi Bhushan of BrightChamps, Amit Ratanpal of Blinc Management, Sachin Anand of Intel, and Dipen Shah of VAG-group), validating that India's largest e-commerce company saw strategic potential in AI-powered physiotherapy. In September 2025, FlexifyMe raised ₹20 crore ($2.4 million) in pre-Series A funding led by IvyCap Ventures with participation from Signal Ventures and existing investors. The new capital is accelerating hybrid care expansion (online plus offline centres), the launch of advanced posture and gait analysis labs, and clinical research partnerships. The company plans to open hybrid care centres and posture/gait labs across Pune, Mumbai, and Bengaluru.